Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has partnered with Ehave Inc., a provider of digital therapeutics for the psychedelic and mental health sectors. The partnership is intended to change the fact that although there are currently 250 identified biochemical markers about a broad range of the body’s organic system and how they function, the approach to utilize them to improve diagnostic accuracy and patient outcomes remains challenging for psychiatric disorders. Additionally, experts caution that even though a potential breakthrough has been found pertaining to treating a range of mental illnesses, which could have profound implications for a space that has seen few pharmacological advancements over recent decades, more research is needed. “This is where the partnership between Brain Scientific and Ehave can potentially make a difference,” reads a recent article. “The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI linked data protocols to develop neural net algorithms.” The collaborators will use the data and algorithms to “statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia.”
To view the full article, visit https://ibn.fm/vggxi
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
